tiprankstipranks
Trending News
More News >

Sanofi’s Beyfortus Shows High Effectiveness Against RSV

Sanofi (SNY) has released an update.

Confident Investing Starts Here:

Sanofi showcases the effectiveness of their infant RSV vaccine, Beyfortus, at IDWeek 2024, with data demonstrating over 80% real-world effectiveness in preventing disease and hospitalization. Beyfortus, which is approved in several regions including the US and EU, is designed to protect all infants through their first RSV season, with new manufacturing lines established to meet global demand.

For further insights into SNY stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App